Have a personal or library account? Click to login
Effects of Long-Term Treatment with Atorvastatin and Rosuaastatin on Active Avoidance Test in Intact Rats Cover

Effects of Long-Term Treatment with Atorvastatin and Rosuaastatin on Active Avoidance Test in Intact Rats

Open Access
|Nov 2016

References

  1. 1. van der Most PJ, Dolga A,Nijholt I, Luiten P, Eisel U. Statins: Mechanisms of neuroprotection. Prog Neurobiol. 2009;88(l):64-75.10.1016/j.pneurobio.2009.02.00219428962
  2. 2. Masse I, Beordet R, Deplanque D, A1K, Richard F, Libersa et al. Lipid lowering drugs are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005; 76(12): 1624-9.10.1136/jnnp.2005.063388173946616291883
  3. 3. Jick H, Zomberg GL, Jick S, Seshadri S, Drachman DA. Statins and the risk of dementia, The Lancet. 2000;356:1627-31.
  4. 4. Bemick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65(9): 1388-94.10.1212/01.wnl.0000182897.18229.ec16275825
  5. 5. Parle M, Singh N. Reversal of memory deficits by Atorvastatin and Simvastatin in Rats. Yakugaku Zasshi. 2007; 127(7): 1125-37.10.1248/yakushi.127.112517603272
  6. 6. Evans MA, Golomb BA, Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800-l 1.10.1592/phco.29.7.80019558254
  7. 7. Padala KP, Padala PR, Potter JF, Simvastatin-induced decline in cognition, Ann Pharmacother. 2006;40( 10): 1880-3.10.1345/aph.1H01416940411
  8. 8. Kalonia H, Kumar P, Kumar A. Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats. Behav Brain Res. 2011;216(1): 220-8.10.1016/j.bbr.2010.07.04020696189
  9. 9. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007;206(1): 56-69.10.1016/j.expneurol.2007.03.03117521631
  10. 10. Ucak A, Onan B, Guler A, Sahin MA, KihqkayaO, Oztaș E, et al. Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfesion-induced spinal cord tissue injury in rats. Ann Vase Surg. 2011;25(5):686-95.10.1016/j.avsg.2011.02.02421724106
  11. 11. Baytan SH, Alkanat M, Okuyan M, Ekinci M, Gedikli E, Ozeren M, et al. Simvastatin impairs spatial memory in rats at a specific dose level. Tohoku J Exp Med. 2008;214(4):341 -9.10.1620/tjem.214.34118441510
  12. 12. Baytan SH, Alkatan M, Ozeren M, Ekinci M, Akgun A. Fluvastatin alters psychomotor performance and daily activity but not the spatial memory in rats. Tohoku J Exp Med. 2006,209(4), 311-20.
  13. 13. Douma TN, Borre Y, Hendriksen H, Olivier B, Oosting RS. Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. Psychopharmacology. 2011 ;216(4):537-44.10.1007/s00213-011-2245-0
  14. 14. Vaughan CJ. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol.2003;91(4A):23B-29B.10.1016/S0002-9149(02)03270-8
  15. 15. Wang Q, Zengin A, Deng C, Li Y, Newell KA, Yang GY, et al. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the upregulation of NMDA receptor binding in the rat brain. Exp Neurol. 2009;216( 1): 132-8.10.1016/j.expneurol.2008.11.016
  16. 16. Magnusson KR, Cotman C W. Effects of aging on NMDAnand MK801 binding sites in mice. Brain Res. 1993 ;604( 1 -2) :334-7.10.1016/0006-8993(93)90386-2
  17. 17. Malenka RC, Nicoll RA. Long-term potentiation-a decade of progress? Science 1999; 285(5435): 1870-4.
Language: English
Page range: 24 - 28
Submitted on: Jan 16, 2013
|
Accepted on: Jun 26, 2013
|
Published on: Nov 30, 2016
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2016 Maria T. Georgieva-Kotetarova, Ivanka I. Kostadinova, Delian P. Delev, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.